Parkinson's Disease
19 videos · last 6 months shuffled daily, then older videos newest first
▶
22:15 Delivering Advanced Neurotherapy Trials
Professor Liam Gray, director of the BRAIN Unit, and Professor Anne Rosser of Cardiff University discuss delivering trials of gene, RNA and cell therapies for Huntington's and Parkinson's diseases, for the Centre for Trials Research.
▶
51:44 What Should Mild Cognitive Impairment Trials Measure?
University of Bristol senior research associate Victoria presents a core outcome set for mild cognitive impairment trials, developed with people with MCI, family members, researchers and healthcare professionals, in a Dementia Researcher session.
▶
2:38 FDA Approves Tavapadon for Parkinson’s Motor Symptoms
The Michael J. Fox Foundation outlines the FDA approval of tavapadon, a once-daily medication for Parkinson's motor symptoms.
▶
1:46 Evidence, Treatment Experience, and Emerging Advances of Subcutaneous Apomorphine Infusion in PD
Francesca Morgante, MD, PhD, of St George's University of London on the TOLEDO trial evidence for subcutaneous apomorphine infusion in Parkinson's, which improved daytime mobility and nighttime symptoms.
▶
1:13:06 Parkinson's Disease Modification and Stem Cell Research
Michael S. Okun, MD, of the Norman Fixel Institute for Neurological Diseases reviews where Parkinson's disease-modifying research stands, including cell replacement therapies, disease-modifying trials and ethics, for the Parkinson's Foundation.
▶
23:05 Moonshots & Milestones: The Future of Neurodegeneration Drug Discovery, AD/PD™ Session Spotlight
A fireside debate from the AD/PD 2026 International Conference on whether the future of neurodegeneration drug discovery lies with startups, big pharma or academia.
▶
57:59 Optimizing Parkinson's Disease Clinical Trials
Pete Schmidt, PhD, Chief Scientific Officer, and Amber Anderson, Senior Project Manager, of Dr. Vince Clinical Research discuss design, endpoints and execution of symptomatic and disease-modifying Parkinson's trials, with the Davis Phinney Foundation.
▶
36:16 The Science Behind Parkinson's Clinical Trials, Part 1
Dr. Kevin McFarthing, a biochemist and expert in Parkinson's clinical trials, joins the APDA to explain the biology behind therapies in Parkinson's trials, from gene therapies and antisense oligonucleotides to cell-replacement and antibody therapies.
▶
5:14 Dopamine Neuron Cell Replacement Therapy for Parkinson's Disease with Melita Petrossian, MD
Melita Petrossian, MD, on the trials now testing dopamine neuron cell replacement in Parkinson's disease, which loses the neurons that release dopamine to control movement.
▶
9:33 Racial and Ethnic Diversity in Parkinson's Drug Trials
Dr. Farley Reis Rodrigues and Dr. Daniel Di Luca present their systematic review of racial and ethnic diversity in trials of disease-modifying drugs for Parkinson's disease, for the International Parkinson and Movement Disorder Society.
▶
35:01 Phase III Parkinson’s Data from Annovis Bio
An investor webcast from Annovis Bio announcing new data from Phase III Parkinson’s Study.
▶
59:09 Annovis Patients' Live Forum: Your Questions Answered (February 27, 2025)
Annovis Bio CEO Maria Maccecchini updates patients on the Phase 3 Alzheimer's trial and plans for Phase 3 Parkinson's and open-label extension studies, and takes audience questions.
▶
3:26 Ambroxol, a Drug Used for Coughs, Will Start Clinical Trials for Parkinsons
Cure Parkinson's video on ASPro-PD, a large-scale Phase 3 clinical trial of ambroxol aimed at establishing its potential to slow the progression of Parkinson's.
▶
4:53 In a Matter of Weeks Parkinson's Disease Patients Saw Breakthrough With Non-Invasive Vibrations
Parkinson's Disease patients were treated with non-invasive vibrations using a glove in a clinical trial from researchers at Stanford University.
▶
19:37 AAV-Based Gene Therapy in Parkinson's Disease
Michael S. Okun, MD, and Joohi Jimenez-Shahed, MD, review AAV-based gene therapy strategies for Parkinson's disease, safety and durability, and endpoints and outcomes from ongoing gene therapy studies, in a Medscape education programme.
▶
3:21 EJS ACT-PD: A Platform Trial for Parkinson's
Cure Parkinson's explains EJS ACT-PD, a UCL-led multi-arm, multi-stage platform trial testing several potentially disease-modifying Parkinson's treatments against a shared placebo group in 1,600 people, which in October 2025 was open for recruitment.
▶
31:14 A Decade of LRRK2 and GBA1 Trials in Parkinson's
Aleks Pilcicka, Research Liaison Officer at Cure Parkinson's, gives an overview of recent clinical trials of therapies targeting LRRK2 and GBA1, two genetic risk factors for Parkinson's, at the 2025 Rallying to the Challenge meeting in Grand Rapids.
▶
58:46 Annovis Webinar and Live Q&A - June 24, 2025
Annovis CEO Maria Maccecchini, Ph.D., gives updates on the company's Phase 3 trial in early Alzheimer's and next steps for its Parkinson's programme, and answers audience questions.
▶
48:44 Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo
Dr. Joseph Palumbo, chief medical officer at BioVie Pharma, on moving from academic research to drug development, and the long road to an FDA-approved ALS treatment.